PMID- 9700986
OWN - NLM
STAT- MEDLINE
DCOM- 19981014
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 32
IP  - 2
DP  - 1998 Aug
TI  - Antiarrhythmic effects of a novel class III drug, KCB-328, on canine ventricular 
      arrhythmia models.
PG  - 239-47
AB  - KCB-328 is a newly synthesized class III drug. To determine whether this drug has 
      antiarrhythmic or proarrhythmic effects, we used canine ventricular arrhythmia 
      models induced by coronary ligation and reperfusion, programmed electrical 
      stimulation (PES), two-stage coronary ligation, digitalis, or epinephrine. 
      KCB-328, in an intravenous infusion of 0.5 mg/kg/30 min, prolonged the QTc 
      interval only 11%, but had antiarrhythmic effects on the reentry arrhythmias 
      induced by PES (12 of 12 dogs with old myocardial infarction; p < 0.05). KCB-328, 
      in an infusion of 1 mg/kg/h, suppressed the occurrence of fatal ventricular 
      fibrillation (VF) induced by coronary ligation and reperfusion under either 
      halothane anesthesia (p < 0.05) or pentobarbital anesthesia (p < 0.05). Under the 
      halothane anesthesia, KCB-328 alone showed proarrhythmic effects [i.e., induction 
      of ventricular premature contractions (VPCs)], but it did not induce a more 
      severe effect such as torsades de pointes-type ventricular tachycardia (VT). In 
      addition, KCB-328 had weak antiarrhythmic effects on the automaticity arrhythmias 
      induced by 24-h coronary ligation but was effective neither on 48-h coronary 
      ligation arrhythmias nor on the digitalis- and epinephrine-induced arrhythmias. 
      Our results indicate that KCB-328 has powerful antiarrhythmic effects with fewer 
      proarrhythmic potencies.
FAU - Xue, Y
AU  - Xue Y
AD  - Department of Pharmacology, Yamanashi Medical University, Japan.
FAU - Tanabe, S
AU  - Tanabe S
FAU - Nabuchi, Y
AU  - Nabuchi Y
FAU - Hashimoto, K
AU  - Hashimoto K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 
      (1-(2-amino-4-methanesulfonamidophenoxy)-2-(N-(3,4-dimethoxyphenethyl)-N-methylamino)ethane)
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Phenethylamines)
RN  - 0 (Sulfonamides)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Animals
MH  - Anti-Arrhythmia Agents/*therapeutic use
MH  - Arrhythmias, Cardiac/chemically induced/*drug therapy
MH  - Digitalis
MH  - Disease Models, Animal
MH  - Dogs
MH  - Electric Stimulation
MH  - Epinephrine
MH  - Female
MH  - Ligation
MH  - Male
MH  - Myocardial Reperfusion
MH  - Phenethylamines/*therapeutic use
MH  - Plants, Medicinal
MH  - Plants, Toxic
MH  - Sulfonamides/*therapeutic use
EDAT- 1998/08/13 00:00
MHDA- 1998/08/13 00:01
CRDT- 1998/08/13 00:00
PHST- 1998/08/13 00:00 [pubmed]
PHST- 1998/08/13 00:01 [medline]
PHST- 1998/08/13 00:00 [entrez]
AID - 10.1097/00005344-199808000-00011 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1998 Aug;32(2):239-47. doi: 
      10.1097/00005344-199808000-00011.